CSL Behring

CSL Behring is one of the world's leading plasma protein biotherapeutics companies, specializing in the manufacture of therapies for the treatment of rare and serious diseases. Its line of therapies includes products for the treatment of hemophilia, von Willebrand Disease, and other bleeding disorders; immune deficiencies including primary immunodeficiency diseases (PIDD); hereditary angioedema and inherited respiratory disease. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in newborns. The company also operates one of the world's largest plasma collection networks, CSL Plasma.

Company Statistics
Parent Company: CSL Limited, (ASX:CSL), Melbourne, Australia Headquarters: King of Prussia, PA Employees: 9,000+ Operations: In 19 countries President: Paul Perreault R&D: Marburg, Germany; Bern, Switzerland; King of Prussia, Pennsylvania, USA; Tokyo, Japan; Broadmeadows and Parkville, Victoria, Australia.

History
CSL Behring is a subsidiary of CSL Limited (ASX: CSL), a specialty biopharmaceutical company with headquarters in Parkville, Australia. As part of a global alignment, the CSL Behring brand was established in 2007. Previously known as ZLB Behring, the company has a long history dating back to 1904.

CSL Behring traces its heritage back to Emil von Behring, the inventor of serum therapy or serology.

1901: Emil von Behring was the first recipient of the Nobel Prize in Physiology or Medicine.

1904: Emil von Behring founded the Behringwerke in Marburg, Germany, for the purpose of experimental work on disease prevention and for the manufacture of sera and vaccines.

1913: Behringwerke expands to produce a gas gangrene antiserum and a cholera vaccine.

1916: CSL (then Commonwealth Serum Laboratories) was established in Australia with the goal of providing vaccines to the people of Australia and New Zealand.

1917: CSL produces 3 million doses of a mixed bacterial vacine to combat the 1919 influenza pandemic.

1930: CSL releases its first life-saving antivenom for tiger snake bites.

1940: Armour Pharmaceuticals (a predecessor company) in Kankakee, Illinois, becomes the largest supplier of human albumin (the most abundant protein in human blood plasma) in World War II.

1944: CSL begins producing penicillin on a large scale for the military and Australia is the first country to supply the drug to civilians at no charge.

1949: ZLB (Zentrallaboratorium Blutspendedienst, a predecessor company) is established in Bern, Switzerland, as a department of the Swiss Red Cross and holds its first donor blood sessions in Switzerland.

1954: Australian CSL officer Val Bazeley assists Jonas Salk with the production of the experimental polio vaccine used in the first clinical trials in the US. Bazeley returns to Australia to set up production of the Salk vaccine at CSL.

1966: Rh(D) immunoglobulin, produced from plasma, is introduced by CSL for haemolytic disease in newborns.

1981: Behringwerke introduces Haemate® human plasma coagulation factor VIII/von Willebrand factor complex for the treatment of patients with hemophilia A.

1991: CSL Limited is incorporated in Australia.

2000: ZLB Bioplasma (a predecessor company) is established, acquiring the plasma fractionation assets from SRK, a nonprofit organization affiliated with the Swiss Red Cross. ZLB becomes the fifth largest manufacturer of plasma products worldwide.

2001: Aventis Behring (a predecessor company) acquires 42 plasma centers, forming the world's largest plasma collection business.

2004: CSL Limited completes the acquisition of Aventis Behring, combining it with ZLB Bioplasma to create ZLB Behring (later CSL Behring).

2007: ZLB Behring becomes CSL Behring.

2009: ZLB Plasma changes its name to CSL Plasma to align with its parent company, CSL Behring, and opens the world's largest and most advanced plasma testing laboratories in Knoxville, Tennessee.

Products
CSL Behring researches, develops, manufactures and markets a range of plasma-derived and recombinant products and related services, specializing in the treatment of rare and serious diseases. Its line of therapies includes products for the treatment of hemophilia, von Willebrand Disease, and other bleeding disorders; immune deficiencies including primary immunodeficiency diseases (PIDD); hereditary angioedema and inherited respiratory disease. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in newborns.[1]

Immunology:
 * Hizentra®,Human normal immunoglobulin. Liquid 20% immunoglobulin solution, ready-to-use for subcutaneous administration
 * Privigen®, human polyvalent immunoglobulin, liquid 10% solution for intravenous injection
 * Vivaglobin®, human normal immunoglobulin, liquid 16% solution for subcutaneous administration
 * Carimune® NF, Sandoglobulin®, Sanglopor® human normal immunoglobulin, freeze-dried formulations for intravenous administration
 * Sandoglobulin ® NF Liquid, Redimune®, Redimune® NF Liquid, human normal immunoglobulin, liquid 12% solution for intravenous administration
 * Rhophylac® human anti-D immunoglobulin. Prefilled syringes of highly purified anti-Rhesus factor D IgG for intravenous administration and intramuscular injection.
 * Cytogam®, human cytomegalovirus immunoglobulin. Liquid immunoglobulin containing a standardized amount of antibody to cytomegalovirus.
 * Berirab® P, human rabies immunoglobulin, liquid 16% solution for intramuscular injection
 * Beriglobin® P, human hepatitis A immunoglobulin, liquid 16% solution for intramuscular injection
 * Hepatitis B Immunoglobulin P Behring, human hepatitis B immunoglobulin, liquid 16% solution for intramuscular injection
 * Tetagam® P, human tetanus immunoglobulin, liquid 16% solution for intramuscular injection
 * Varicellon® P, human varicella immunoglobulin, liquid 16% solution for intramuscular injection
 * Rhesogamma® P, human anti-D immunoglobulin. Prefilled syringes of highly purified anti-Rhesus factor D IgG for intravenous administration and intramuscular injection.

Coagulation/Bleeding Disorders:
 * Beriate®, freeze-dried human coagulation factor VIII concentrate
 * Berinin® P, freeze-dried human coagulation factor IX concentrate
 * Helixate® FS and Helixate® NexGen, freeze-dried recombinant coagulation factor VIII
 * Humate-P® and Haemate® P, freeze-dried human coagulation factor VIII: C and von Willebrand factor concentrate
 * Monoclate P®, a freeze-dried monoclonal antibody purified human coagulation factor VIII concentrate
 * Mononine®, a freeze-dried human coagulation factor IX that has been purified using monoclonal antibodies
 * Stimate®, a synthetic desmopressin acetate nasal spray
 * Factor X P Behring, a freeze-dried human coagulation factor IX and factor X concentrate
 * Fibrogammin® P and Corifact™, freeze-dried human coagulation factor XIII concentrate
 * Octostim®, a synthetic desmopressin acetate nasal spray

Pulmonary:
 * Zemaira®, freeze-dried Human Alpha1-proteinase inhibitor (A1-PI)

Critical Care:
 * Beriplex® P/N, freeze-dried human prothrombin complex concentrate
 * Haemocomplettan® P, RiaSTAP™, freeze-dried human fibrinogen (factor I) concentrate
 * Kybernin® P, freeze-dried human antithrombin III concentrate
 * AlbuRx®, Alburex, Human Albumin Behring, Albuminar® 25, human albumin solution (5%, 20% or 25% human albumin solutions)
 * Berinert® P, freeze-dried human C1-esterase inhibitor (C1-INH) concentrate
 * Streptase®, freeze-dried streptokinase

Wound Healing:
 * Beriplast® P Combi-Set, fibrin sealant kit, freeze-dried fibrin sealant for topical application
 * Fibrogammin® P, freeze-dried human coagulation factor XIII concentrate
 * TachoComb®, fibrin sealant fleece-type, fleece-type collagen preparations coated with fibrin glue components

(Note: Product availability varies from country to country, depending on registration status.)

Offices
The company is headquartered in King of Prussia, Pennsylvania. It has 9,000+ employees in 19 countries. Major manufacturing centers are located in Bern, Switzerland, Marburg, Germany and Kankakee, Illinois.

Finances
CSL Behring's product sales in their fiscal year 2010/2011 were approximately U.S.$ 3.314 billion